Who is the CEO of Sam Chun Dang Pharm?

According to the DART company overview, Sam Chun Dang Pharm's representative director is 전인석 (name as registered in Korean). The company was founded on 1943-12-29.

Where is Sam Chun Dang Pharm listed?

Sam Chun Dang Pharm trades on the Korea Exchange KOSDAQ market under the ticker 000250. Its fiscal year ends in December.

Does Sam Chun Dang Pharm pay a dividend?

Yes. For fiscal 2025, Sam Chun Dang Pharm paid a cash dividend of ₩50 per common share, a 0.0% yield as stated in its annual report, with a payout ratio of 22.1%. The prior year's dividend was ₩200.

Does Sam Chun Dang Pharm have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dividend cut (dividend per share lower than, or dropped from, the prior year); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Supply contract (single sales or supply contract disclosed in the past 30 days). These are factual flags, not investment advice.

Which companies are in the same industry as Sam Chun Dang Pharm?

Under the Korean Standard Industrial Classification recorded on DART, Sam Chun Dang Pharm is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

Sam Chun Dang Pharm KRX:000250KOSDAQ

삼천당제약 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days6

DART filings, 7 days0

Articles tracked94since Sep 11

In Q2 2026, Sam Chun Dang Pharm reported revenue of ₩70.7bn, up 24.3% year on year, and operating profit of ₩3.4bn. Sam Chun Dang Pharm (삼천당제약) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 2 articles. The most common catalyst was clinical & approvals (1).

Filing signals Turnaround Supply contract Dividend cut Share pledge Screener

Sam Chun Dang Pharm quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩70.7bn	+24.3%	₩3.4bn margin 4.9%	₩6.2bn
Q1 2026	₩64.9bn	+28.2%	₩5.4bn margin 8.4%	₩6.9bn
Q4 2025 derived	₩66.3bn	+20.1%	₩5.4bn margin 8.2%	₩7.9bn
Q3 2025	₩58.0bn	+10.8%	₩3.4bn margin 5.9%	₩4.5bn
Q2 2025	₩56.9bn	+3.7%	−₩1.1bn margin −1.9%	−₩1.6bn
Q1 2025	₩50.6bn	+4.5%	₩688m margin 1.4%	₩1.3bn
Q4 2024 derived	₩55.2bn	+5.1%	−₩545m margin −1.0%	−₩8.9bn
Q3 2024	₩52.4bn	+8.1%	−₩814m margin −1.6%	−₩285m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Sam Chun Dang Pharm top stories 2 weeks, by number of outlets

1
삼천당제약 과거 美 등록 안약 브랜드 위조품서 세균 검출…FDA 경고
1 outlets · 1 articlesFirst report Oct 17 09:18 뉴스락Regulatory approval
2
최근 5거래일 삼천당제약 주가 흐름
1 outlets · 1 articlesFirst report Oct 24 13:31 중앙이코노미뉴스
3
삼천당제약 주가, 10월 20일 장중 207,000원 1.66% 하락
1 outlets · 1 articlesFirst report Oct 20 13:32 중앙이코노미뉴스
4
삼천당제약 주가, 10월 21일 장중 210,000원 2.44% 상승
1 outlets · 1 articlesFirst report Oct 21 11:33 중앙이코노미뉴스
5
삼천당제약 주가, 10월 22일 장중 201,000원 5.41% 하락
1 outlets · 1 articlesFirst report Oct 22 14:46 중앙이코노미뉴스
6
삼천당제약 주가, 10월 26일 장중 191,900원 3.66% 하락
1 outlets · 1 articlesFirst report Oct 26 11:29 중앙이코노미뉴스

Latest Sam Chun Dang Pharm news Korean headlines

Oct 2915:11

삼천당제약 주가, 10월 29일 장중 189,100원 0.47% 하락
중앙이코노미뉴스
Oct 2910:32

삼천당제약, 에피나스틴 점안제 시장 급여 진입…경쟁구도 변화 예상
메디팜스투데이
Oct 2818:04

삼천당제약 주가, 10월 28일 애프터마켓 189,900원 1.23% 상승
중앙이코노미뉴스
Oct 2710:24

삼천당제약, 3거래일 만에 상승 전환…4.87% 뛰며 19만8100원
CBC뉴스
Oct 2611:29

삼천당제약 주가, 10월 26일 장중 191,900원 3.66% 하락
중앙이코노미뉴스
Oct 2413:31

최근 5거래일 삼천당제약 주가 흐름
중앙이코노미뉴스
Oct 2314:53

삼천당제약 '먹는 인슐린' 임상 마쳐…흡수율·약효 시험대
뉴스핌
Oct 2214:46

삼천당제약 주가, 10월 22일 장중 201,000원 5.41% 하락
중앙이코노미뉴스
Oct 2209:47

[쩐의흔적] 삼천당제약 회장 딸·사위, 주식담보대출 700억원…보유주식 절반 넘게 담보
더퍼블릭
Oct 2111:33

삼천당제약 주가, 10월 21일 장중 210,000원 2.44% 상승
중앙이코노미뉴스
Oct 2015:04

삼천당제약, 의약품 공급 넘어 '생명 나눔'…임직원 헌혈 동참
파이낸셜뉴스
Oct 2013:32

삼천당제약 주가, 10월 20일 장중 207,000원 1.66% 하락
중앙이코노미뉴스
Oct 1915:59

[한지연의 B스토리]'거위의 꿈'이었을까...삼천당제약의 '증명의 시간'
아주경제
Oct 1911:44

삼천당제약 주가, 10월 19일 장중 202,500원 0.98% 하락
중앙이코노미뉴스
Oct 1709:18

Major삼천당제약 과거 美 등록 안약 브랜드 위조품서 세균 검출…FDA 경고
뉴스락Regulatory approval
Oct 1612:18

삼천당제약 주가, 10월 16일 장중 205,000원 6.38% 상승
중앙이코노미뉴스
Oct 1512:26

삼천당제약 주가, 10월 15일 장중 191,900원 6.84% 하락
중앙이코노미뉴스
Oct 1510:57

삼천당제약 주가 6.99% 급락…19만1600원으로 밀려, 반려동물 구강보조제 유통 확대 주목
CBC뉴스
Oct 1412:06

삼천당제약 주가, 10월 14일 장중 206,000원 2.14% 하락
중앙이코노미뉴스
Oct 1410:24

삼천당제약, 반려동물 구강케어 '덴탈바이오' 유통망 다각화
메디파나뉴스
Oct 1409:15
삼천당제약, 반려동물 구강보조제 ‘덴탈바이오’ 유통 확대…동물병원·방문판매 진출
이투데이
2 more on this story · 2 outlets
- 삼천당제약, 반려동물 구강보조제 ‘덴탈바이오’ 유통 채널 확대더바이오 · Oct 14 10:46
- 삼천당제약, 반려동물 구강보조제 '덴탈바이오' 유통망 확대PRESS9 · Oct 14 11:10
Oct 1312:25

삼천당제약 주가, 10월 13일 장중 204,000원 4.00% 하락
중앙이코노미뉴스
Oct 1214:08

삼천당제약 주가, 10월 12일 장중 213,500원 12.32% 하락
중앙이코노미뉴스
Oct 1209:45

Breaking삼천당제약 VI 발동, 주가 주초장 약세흐름
CBC뉴스
Oct 814:42

삼천당제약 주가, 10월 8일 장중 234,500원 2.70% 하락
중앙이코노미뉴스
Oct 812:51

"10년 선제 투자의 결실"…삼천당제약 '라타스트', 국내 라타노프로스트 일회용 시장 점유율 11% 돌파
더페어뉴스
Oct 810:24

삼천당제약, 일회용 녹내장 시장서 점유율 ‘쑥’
한스경제
Oct 809:46
삼천당제약 "녹내장 치료제 '라타스트', 점유율 11% 돌파"
데일리한국
2 more on this story · 2 outlets
- 삼천당제약 '라타스트', 점유율 11% 돌파 外딜사이트TV · Oct 8 10:16
- 삼천당제약, 녹내장 점안액 '라타스트' 점유율 11% 돌파핀포인트뉴스 · Oct 8 15:44
Oct 809:23
삼천당제약 "녹내장치료제, 시장점유율 11% 돌파"
뉴시스경제
1 more on this story · 1 outlets
- 삼천당제약 녹내장치료제, 시장점유율 11% 돌파파이낸셜포스트 · Oct 8 14:43
Oct 808:54

오리지널 제약사에 되파는 삼천당제약…녹내장 시장서 존재감
파이낸셜뉴스

Articles per day 2 weeks

117

219

220

121

222

123

124

126

127

128

229

Company profile

CEO: 전인석
Industry: Pharmaceuticals
Founded: 1943-12-29
Fiscal year-end: December
Head office: 경기도 화성시
Website: scd.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Sam Chun Dang Pharm dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩50	0.0%	22.1%
FY2024	₩200	0.1%	-42.6%
FY2023	–	–	-8.6%

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

윤대인37.61%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	656
Yuhan	₩66.9bn	492
Daewoong Pharma	₩68.1bn	376
GC Biopharma	₩1.7bn	330
DongKookPharmaceutical	₩26.1bn	256
Daewon Pharmaceutical	−₩9m	201
Kwangdong Pharmaceutical	₩2.8bn	187
JW Pharmaceutical	₩33.3bn	185

Compare Sam Chun Dang Pharm side by side with these companies

Sam Chun Dang Pharm DART filings

Oct 2016:51

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 816:09

Other [기재정정]반기보고서 (2026.06)
Other
Oct 816:05

Other [기재정정]분기보고서 (2026.03)
Other
Oct 115:55

Supply contract [기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 공급계약 체결 및 중동 6개 국가 추가 계약 체결)
Contracts & investment

Catalysts 2 weeks

Clinical & approvals1

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Sam Chun Dang Pharm FAQ

Who is the CEO of Sam Chun Dang Pharm?: According to the DART company overview, Sam Chun Dang Pharm's representative director is 전인석 (name as registered in Korean). The company was founded on 1943-12-29.
Where is Sam Chun Dang Pharm listed?: Sam Chun Dang Pharm trades on the Korea Exchange KOSDAQ market under the ticker 000250. Its fiscal year ends in December.
What were Sam Chun Dang Pharm's latest quarterly results?: In Q2 2026, Sam Chun Dang Pharm reported revenue of ₩70.7bn, up 24.3% year on year, and operating profit of ₩3.4bn. Figures come from reports filed on DART.
Does Sam Chun Dang Pharm pay a dividend?: Yes. For fiscal 2025, Sam Chun Dang Pharm paid a cash dividend of ₩50 per common share, a 0.0% yield as stated in its annual report, with a payout ratio of 22.1%. The prior year's dividend was ₩200.
Does Sam Chun Dang Pharm have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dividend cut (dividend per share lower than, or dropped from, the prior year); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Supply contract (single sales or supply contract disclosed in the past 30 days). These are factual flags, not investment advice.
Which companies are in the same industry as Sam Chun Dang Pharm?: Under the Korean Standard Industrial Classification recorded on DART, Sam Chun Dang Pharm is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.